Literature DB >> 17026816

Cell-free DNA concentration in pleural fluid and serum: quantitative approach and potential prognostic factor in patients with cancer and pleural effusions.

Susana Benlloch1, Juan Luis Martí-Ciriquián, José Marcelo Galbis-Caravajal, Concepción Martín, José Sánchez-Payá, José Manuel Rodríguez-Paniagua, Santiago Romero, Bartomeu Massutí.   

Abstract

PURPOSE: The presence of pleural effusions in patients with tumors is often indicative of locally advanced or metastatic disease, and detection of malignancy in effusion samples frequently leads to a disease upstaging. Our purpose was to quantify the DNA in pleural effusion and serum in patients presenting pleural effusion in order to assess the potential prognostic impact. PATIENTS AND METHODS: The DNA level was determined by amplifying hRNase P in paired samples of serum and pleural fluid in 70 consecutive patients with cancer showing pleural effusion. A group of 30 patients without cancer was included. The correlation between serum and pleural DNA was calculated. Survival curves according to serum and pleural DNA were analyzed.
RESULTS: Median DNA concentrations were greater in patients with neoplasia than in patients without malignancy: 105 ng/mL versus 40 ng/mL (P = 0.001) in serum samples, respectively; 93 ng/mL versus 21 ng/mL (P = 0.001) in pleural fluids, respectively. A positive correlation between serum and pleural levels was confirmed (r = 0.3; P < 0.05). Median survival time for patients with serum DNA < or = 105 ng/mL was 11.03 months in contrast to only 3.63 months for patients with higher values (P = 0.036). Accordingly, median survival time for patients with pleural DNA < or = 93 ng/mL was 12.3 months versus only 4.63 months in case of higher levels (P = 0.027).
CONCLUSION: This study shows that there is a strong correlation between higher levels of free DNA in pleural fluid or serum and malignancy. Survival is worse for patients with higher DNA levels in serum and pleural fluid.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17026816     DOI: 10.3816/CLC.2006.n.043

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  10 in total

Review 1.  Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.

Authors:  Bert Gold; Milena Cankovic; Larissa V Furtado; Frederick Meier; Christopher D Gocke
Journal:  J Mol Diagn       Date:  2015-05       Impact factor: 5.568

2.  Effects of extracellular DNA on plasminogen activation and fibrinolysis.

Authors:  Andrey A Komissarov; Galina Florova; Steven Idell
Journal:  J Biol Chem       Date:  2011-10-05       Impact factor: 5.157

Review 3.  Liquid Biopsies for Cancer: Coming to a Patient near You.

Authors:  Nithya Krishnamurthy; Emily Spencer; Ali Torkamani; Laura Nicholson
Journal:  J Clin Med       Date:  2017-01-04       Impact factor: 4.241

4.  Diagnosis of Parapneumonia Pleural Effusion with Serum and Pleural Fluid Cell-Free DNA.

Authors:  Chih-Min Su; Chia-Te Kung; Sheng-Yuan Hsiao; Nai-Wen Tsai; Yun-Ru Lai; Chih-Cheng Huang; Hung-Chen Wang; Wei-Che Lin; Ben-Chung Cheng; Yu-Jih Su; Cheng-Hsien Lu
Journal:  Biomed Res Int       Date:  2019-03-04       Impact factor: 3.411

5.  Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer.

Authors:  Lin Tong; Ning Ding; Xiaoling Tong; Jiamin Li; Yong Zhang; Xiaodan Wang; Xiaobo Xu; Maosong Ye; Chun Li; Xue Wu; Hairong Bao; Xin Zhang; Qunying Hong; Yuanlin Song; Yang W Shao; Chunxue Bai; Jian Zhou; Jie Hu
Journal:  Theranostics       Date:  2019-07-28       Impact factor: 11.556

6.  Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC.

Authors:  Xuejing Chen; Kun Li; Zichen Liu; Fei Gai; Guanshan Zhu; Shun Lu; Nanying Che
Journal:  Cancer Med       Date:  2021-03-03       Impact factor: 4.452

7.  Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas.

Authors:  Krishna B Sriram; Vandana Relan; Belinda E Clarke; Edwina E Duhig; Morgan N Windsor; Kevin S Matar; Rishendran Naidoo; Linda Passmore; Elizabeth McCaul; Deborah Courtney; Ian A Yang; Rayleen V Bowman; Kwun M Fong
Journal:  BMC Cancer       Date:  2012-09-25       Impact factor: 4.430

Review 8.  Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy.

Authors:  Jun Lu; Baohui Han
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

Review 9.  Technical and Methodological Aspects of Cell-Free Nucleic Acids Analyzes.

Authors:  Zuzana Pös; Ondrej Pös; Jakub Styk; Angelika Mocova; Lucia Strieskova; Jaroslav Budis; Ludevit Kadasi; Jan Radvanszky; Tomas Szemes
Journal:  Int J Mol Sci       Date:  2020-11-16       Impact factor: 5.923

10.  A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer.

Authors:  Shidai Jin; Chengzhi Zhou; Xue Hou; Zaiwen Fan; Jun Zhao; Xinghao Ai; Yuxing Chu; Rongrong Chen; Renhua Guo; Likun Chen
Journal:  Transl Lung Cancer Res       Date:  2020-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.